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VitiligoAbstract Radiation induced depigmentation disorder is a rare accompaniment. We herein report
two patients of bilateral breast cancer developing depigmentation disorder, initially conﬁned to the
radiation portal with subsequent generalization within few months of completion of whole breast
radiotherapy. Both these patients had no prior history of vitiligo or other autoimmune disorder.
This brief report highlights the importance of awareness of this association in appropriate decision
making in susceptible patients thereby preventing this morbidity and its psychological ramiﬁcations.
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Radiotherapy is known to cause hyperpigmentation of the
skin. Hypopigmentation or depigmentation of the skin in the
radiation portal is relatively uncommon. In patients with a his-
tory of vitiligo, depigmentation of the skin in the radiation
portal has been described in patients of cancer of breast or
other sites [1–4]. This is commonly ascribed to Koebner’s phe-
nomenon and apoptosis of susceptible melanocytes due to
radiation induced free radical mediated damage [1–4]. How-
ever such an event in patients without predisposition is extre-
mely rare. We have brought into focus two patients of
bilateral breast cancer developing depigmentation disorder,
initially conﬁned to the radiation portal with subsequentgeneralization within few months of completion of whole
breast radiotherapy. This report emphasizes the importance
of awareness of this rare radiation accompaniment in appro-
priate decision making in vulnerable patients thereby prevent-
ing this morbidity and its psychological consequences.
Clinical case 1
A 40 year old premenopausal woman presented with progres-
sively increasing painless lump in the right breast. She did not
have any past or family history of depigmentation disorder.
Bilateral mammogram suggested lesions in both breasts, BIR-
ADS IV. Trucut biopsy from right breast lump showed inﬁl-
trating ductal carcinoma (IDC). The tumor expressed
estrogen and progesterone receptor and was negative for
Her2/neu receptor. The possibility of invasive cancer could
not be ruled out from ﬁne needle aspiration cytology (FNAC)
from the left breast lump. FNAC from right axillary lymph
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emission tomography-computed tomography (PET-CT) scan
showed a 5 · 4 cm lesion in upper outer quadrant of the right
breast with overlying skin thickening. Another lesion of size
0.8 · 1 cm with mild ﬂuorodeoxyglucose (FDG) uptake was
discerned below the larger lesion. There was a 2.5 · 1.6 cm
lesion in upper outer quadrant of the left breast. Bilateral axil-
lary lymph nodes were enlarged. Bilateral pulmonary metasta-
ses and multiple sclerotic lesions in the right acetabulum, right
ala of sacrum and neck of left scapula were observed. She was
diagnosed with bilateral breast cancer; right cT4bN2M1 and
left cT2N1M1 and was administered 6 cycles of systemic che-
motherapy with DE regimen (Inj. Docetaxel 75 mg/m2 IV D1;
Inj. Epirubicin 80 mg/m2 IV D1 q 3 weekly). She attained good
symptomatic relief and partial response to chemotherapy
(2.7 · 2.2 cm residuum in the right breast and no residuum in
the left breast with complete resolution of pulmonary and
osseous metastases). She was offered the options of mastec-
tomy and breast conservation therapy and in view of young
age she chose the latter. Subsequently she underwent bilateral
breast conservation surgery (wide local excision of lump with
axillary lymph node dissection). The post-operative histopa-
thology report showed tumors of size 2 · 1.5 · 1 cm in the
right breast and 1 · 1 · 0.5 cm in the left breast, IDC. The bio-
marker status was noted to be estrogen and progesterone
receptor positive and Her2/neu receptor negative. All margins
were free. Four out of 13 lymph nodes in the right axilla and 4
out of 12 lymph nodes in the left axilla were found to be
involved. She received bilateral locoregional radiotherapy to
breast, supraclavicular fossa and axilla 50 Gray/25 fractions/
5 weeks followed by boost 16 Gray/8 fractions/1.5 week. Radi-
ation to the breast was planned by bitangential ﬁelds withFig. 1 Depigmented patches in patient 1 involving (A) breast, ch
Depigmented patches in patient 2 involving (D) breast, chest wall, nec
whole breast radiotherapy (F) scalp and around body oriﬁces like the15wedge pair using Cobalt 60 gamma (c) rays (average energy
1.25 MeV) on Theratron (TH) 780E machine (Kirloskar Tech-
nologies private limited). A direct ﬁeld was used with Cobalt
60 gamma (c) rays to cover the supraclavicular fossa and axilla
and dose was prescribed at a depth of 4 cm. Subsequently she
was started on tablet Tamoxifen 20 mg OD and Inj. Zoledron-
ic acid 4 mg IV 4 weekly.
Three months after completion of radiotherapy she devel-
oped nonpruritic depigmented patches, initially involving the
breast, chest wall and neck. Gradually within 4 and 5 months
it generalized involving the upper and lower extremities, abdo-
men and groin. There was no associated induration, atrophy
or scaling of skin (Fig 1A–C). The patient did not opt for
repigmentation therapy. Follow-up PET-CT scan showed pro-
gressive disease in the bone. She received palliative RT 8 Gray/
single fraction to painful bony sites and hormonal therapy was
changed to Inj. Goserelin 10.8 mg subcutaneous q 3 month
along with tablet Letrozole 2.5 mg OD. Following further pro-
gression in bone disease hormonal therapy was changed to Inj.
Goserelin 10.8 mg subcutaneous q 3 month along with tablet
Exemestane 25 mg OD and tab Ibandronate 50 mg OD was
added.Clinical case 2
A 58 year old postmenopausal woman presented with progres-
sively increasing painful lump in the right breast. She did not
have any past or family history of depigmentation disorder.
Bilateral mammogram suggested a lesion in the right breast,
BIRADS 5. She underwent right sided breast conservation sur-
gery (wide local excision of lump with axillary lymph node dis-est wall and neck (B) upper extremities (C) lower extremities.
k and upper extremities (E) coalescing in the radiation portal for
mouth, nose and eyes.
Radiation induced depigmentation disorder 103section). Post-operative histopathology report showed a
5 · 2.5 · 2.5 cm tumor, IDC. Fifteen lymph nodes were dis-
sected and all were free. Subsequently she underwent right
sided whole breast radiotherapy (50 Gray/25 fractions/5 weeks
and boost 16 Gray/8 fractions/1.5 week). Radiation to the
breast was planned by bitangential ﬁelds with 15wedge pair
using Cobalt 60 gamma (c) rays (average energy 1.25 MeV)
on Theratron (TH) 780E machine (Kirloskar Technologies pri-
vate limited). This was followed by 6 cycles of adjuvant chemo-
therapy with CMF regimen (Inj. Cyclophosphamide 600 mg/
m2 IV D1; Inj. Methotrexate 40 mg/m2 IV D1, Inj. 5ﬂuoroura-
cil 600 mg/m2 IV D1 q 3 week). She developed nonpruritic
depigmented patches in the right breast 1 month after comple-
tion of radiation therapy. Subsequently the lesions generalized
to the face, neck, abdomen, upper and lower extremities. There
was no associated induration, atropy or scaling of the skin (Fig
1D–F). The patient did not opt for repigmentation therapy.
She thereafter completed 5 years of hormonal therapy with
tablet Tamoxifen 20 mg OD. After 7 years of follow-up she
developed a lump in the left breast. Bilateral mammogram
showed a suspicious lesion in outer-inferior quadrant of the
left breast, BIRADS 5. Trucut biopsy from the left breast lump
showed foci of ductal carcinoma in situ. She underwent left
sided breast conservation surgery (wide local excision of lump
with axillary lymph node dissection). Post-operative histopa-
thology showed a 1 · 1 · 0.8 cm tumor, IDC, grade 2. The bio-
marker status was noted to be estrogen and progesterone
receptor negative. Four out of 12 lymph nodes were found
to be pathologically involved. Subsequently she underwent left
sided whole breast radiotherapy (50 Gray/25 fractions/5 weeks
and boost 16 Gray/8 fractions/1.5 week) followed by 6 cycles
of adjuvant chemotherapy with DE regimen. She developed
hypopigmented patches in the left breast 1 month after com-
pletion of radiation therapy. Thereafter she is disease free for
the next 5 years.Discussion
Vitiligo is a common skin disorder affecting 1% of the general
population worldwide [5]. The cause of vitiligo is not exactly
known but it may arise from genetic, autoimmune, oxidative
stress, neural or viral cause [6]. The most prominent symptom
is depigmented patch that occurs in the extremities and face.
Depigmentation is particularly noticeable around body oriﬁces
– mouth, eyes, nostril, genitalia and umbilicus. Though not life
threatening, vitiligo causes considerable psychological scarring
and stigma and patients experience depression and similar
mood disorder [7].
The effect of radiotherapy on the skin may be acute or late.
Acute effects are mainly due to loss of cells from the basal
layer of the epidermis whereas late effects are due to endothe-
lial damage. Commonly radiation leads to hyperpigmentation
in the form of skin erythema – dull or bright. Patients with col-
lagen vascular disease have an enhanced sensitivity to ionizing
radiation and may have serious sequel like cutaneous necrosis
or ﬁbrosis [4]. Exacerbation of acute and late dermatological
effects of radiation is unknown in patients of vitiligo [4]. How-
ever, fresh depigmented lesions in the radiation portal have
been previously reported in patients with vitiligo undergoing
radiation therapy for cancer of breast or other sites [1–4].Radiation induced depigmentation disorder can be due to
Koebner’s phenomenon [1,4,8]. Koebner’s phenomenon or iso-
morphic response is described as development of preexisting
skin disease following trauma – mechanical, chemical, thermal
or infectious, to uninvolved skin [4,9]. The probable mecha-
nism is apoptosis of susceptible melanocyte by radiation
induced free radical mediated damage [4]. The increased sensi-
tivity of susceptible melanocytes to oxidative stress may arise
from complex processes of abnormal synthesis and processing
of tyrosinase related protein-1 (TRP-1) and its protein–protein
interaction with calnexin [10]. High levels of thioredoxin and
thioredoxin reductases have been shown to protect from ioniz-
ing radiation-induced cell death. However in keratinocytes of
vitiligo patients, high extracellular calcium levels may inhibit
thioredoxin reductase leading to enhanced sensitivity to radia-
tion induced cell death by auto-cytotoxic mechanism [8].
Keratinocyte-derived factors such as stem cell factor (SCF)
and basic ﬁbroblast growth factor (bFGF) regulate melano-
cyte growth and survival [11]. Apoptosis of keratinocytes can
reduce the level of these factors triggering widespread apopto-
sis of melanocytes with subsequent depigmentation.
Many chemotherapeutics are associated with hyperpigmen-
tation. Conversely hypopigmentation has been rarely associ-
ated with topical exposure to agents like Thiotepa or
systemic exposure to agents like imatinib. The pathogenesis
of hypopigmentation caused by chemotherapeutics includes
deviation in the amount and distribution of melanin pigment
in the epidermis, an alteration in the number of melanocytes
and toxicity to melanocyte [12]. Hypopigmentation in associa-
tion with imatinib has been attributed to inhibition of tyrosine
kinase activity of platelet derived growth factor receptor
(PDGFR) and c-kit, which are believed to be critical in normal
pigmentation [13]. However it is highly unlikely that systemic
chemotherapy has any substantial role in the development of
depigmentation disorder in the illustrative cases.
The brief report includes 2 patients of bilateral breast can-
cer developing depigmentation disorder within a few months
of completion of whole breast radiation therapy. Depigmenta-
tion was initially localized in the radiation portal with subse-
quent generalization. Such pigmentory changes are not
unknown in patients of vitiligo undergoing radiation therapy
for carcinoma of breast or other sites. But the absence of prior
history of depigmentation disorder in both the illustrative
cases is notable. What could be the possible aetiopathogenesis
of this unusual accompaniment? Radiation may lead to cell
death of melanocytes and keratinocytes in the treatment portal
by direct or indirect damage (oxidative stress due to free rad-
ical formation) to DNA. Damage or destruction of melano-
cytes leads to exposure of intracytoplasmic antigens which
may trigger the generation of widespread autoimmune
response by cytotoxic (CD8+) T lymphocytes and helper
(CD4+) T lymphocytes (cell mediated immune response)
and B-lymphocytes (humoral immune response). This causes
subsequent death (apoptosis) or damage of melanocytes out-
side the radiation portal leading to generalized depigmentation
disorder. This is further exacerbated by the critical depletion of
keratinocyte derived growth factors needed for melanocyte
growth and survival. The report highlights the importance of
awareness of this rare accompaniment which may help in pru-
dent decision making e.g. preferring mastectomy to breast con-
servation therapy in susceptible patients. However it is not
104 A. Biswas et al.always easy to identify patients at risk of developing this com-
plication as reﬂected in this brief report. Though not life-
threatening, radiation induced depigmentation disorder has
considerable psychological effects and stigma and prevention
of such morbidity is of paramount importance.
Conclusion
Radiation induced depigmentation disorder in patients with
breast cancer is a rare accompaniment. The case report empha-
sizes the importance of awareness of this association in appro-
priate decision making in susceptible patients thereby
preventing this morbidity and its cosmetic and psychological
ramiﬁcations.
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